General and COPD-specific patient characteristics
| Attribute | Patients with a valid registration | |
| Sociodemographic features | ||
| Age years | 63±9 | 402 (100) |
| Female % | 50 | 402 (100) |
| Partnered % | 71 | 402 (100) |
| Pulmonary function | ||
| FEV1 % predicted | 55±18 | 402 (100) |
| FVC % predicted | 91±17 | 402 (100) |
| FEV1/FVC ratio % | 48±12 | 402 (100) |
| FEV1 reversibility % patients | 36 | 402 (100) |
| GOLD class I/II/III/IV % | 9/48/36/7 | 402 (100) |
| Blood gas analysis | ||
| Hb, mmol·L−1 | 8.9±0.9 | 182 (45) |
| Hb<8.5 (male) or <7.5 (female) % | 22/8 | 91/91 (45) |
| pH | 7.42±0.32 | 245 (61) |
| PaCO2 kPa | 5.15±0.66 | 245 (61) |
| PaCO2 >6.5 kPa % | 3 | 245 (61) |
| PaO2 kPa | 9.46±1.51 | 245 (61) |
| PaO2 <8.0 kPa % | 16 | 245 (61) |
| BIC, mmol·L−1 | 24.7±2.7 | 245 (61) |
| Base excess | 0.67±2.33 | 245 (61) |
| SaO2 % | 94±3 | 245 (61) |
| Comorbidities | ||
| Number of comorbidities (0/1/2/3/4/5/6/7) % | 19/30/22/15/9/2/1/1 | 402 (100) |
| Cardiovascular % | 49 | 402 (100) |
| Metabolic% | 11 | 402 (100) |
| Musculoskeletal % | 17 | 402 (100) |
| Psychiatric % | 13 | 402 (100) |
| Others % | 51 | 402 (100) |
| Pulmonary medication | ||
| Short-acting bronchodilator(s) % | 46 | 402 (100) |
| Long-acting bronchodilator(s) % | 71 | 402 (100) |
| Inhalation steroids % | 52 | 402 (100) |
| Maintenance systemic steroids % | 1 | 402 (100) |
| Burden of disease | ||
| GOLD class (CCQ-based) A/B/C/D % | 11/33/9/47 | 363 (90) |
| CCQ total score points | 1.95±1.05 | 363 (90) |
| CCQ symptom subscore points | 2.36±1.18 | 359 (89) |
| CCQ functional limitation subscore points | 1.84±1.21 | 359 (89) |
| CCQ mental subscore points | 1.28±1.44 | 359 (89) |
| CCQ total score >1.0 % | 80 | 363 (90) |
| BODE index points | 2.8±1.6 | 333 (83) |
| BODE quartile 1/2/3/4 % | 28/54/12/6 | 333 (83) |
| Nonpharmacological interventions in primary care past 12 months | ||
| Patients receiving physiotherapy % | 20 | 402 (100) |
| Patients receiving care from dietician % | 10 | 402 (100) |
| Patients receiving occupational therapy % | 1 | 402 (100) |
| Patients receiving care from psychologist % | 4 | 402 (100) |
| Treatable traits | ||
| Smoking status, current/ex/never % | 44/54/2 | 402 (100) |
| Activity-based dyspnoea, MRC I/II/III/IV/V % | 31/31/25/9/4 | 363 (90) |
| Number of exacerbation past year, 0/1/≥2 or ≥1 hospitalisation % | 52/18/30 | 379 (94) |
| Nutritional status, BMI<21/BMI 21–25/BMI 25–30, BMI 30–35, BMI >35 % | 20/31/28/16/5 | 392 (98) |
| Fatigue, CIS-F score points | 39±12 | 362 (90) |
| Depressed mood, BDI score points | 2.2±2.5 | 360 (90) |
| Physical capacity | ||
| 6MWD m | 461±123 | 382 (95) |
| 6MWD % predicted | 71±18 | 382 (95) |
| Habitual physical activity, steps·day−1 | 5465±3029 | 366 (91) |
| Activation for self-management | ||
| PAM score points | 52±10 | 365 (91) |
| PAM level I/II/III/IV % | 34/28/31/7 | 365 (91) |
Data are presented as %, n (%) or mean±sd. FEV1: forced expiratory volume in 1 s; FVC: forced vital capacity; GOLD: Global Initiative on Obstructive Lung Disease; Hb: haemoglobin; CCQ: Clinical COPD Questionnaire; BODE: BMI, airflow obstruction, dyspnoea, exercise capacity; MRC: Medical Research Council dyspnoea scale; BMI: body mass index; BDI: Beck depression inventory; CIS-F: checklist individual strength-fatigue; 6MWD: 6-minute walking distance; PAM: patient activation measure.